Intellia Therapeutics, Inc. (NTLA) vs Novavax, Inc. (NVAX)
Intellia Therapeutics, Inc. and Novavax, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Novavax, Inc. are of similar size ($1.8B and $1.7B). Intellia Therapeutics, Inc. grew revenue faster over the last twelve months: 12.6% against −61.6%. Novavax, Inc. has the higher net margin (−59.9% vs −672.2%) and the higher return on invested capital (0.00% vs −91.3%). Across the 17 metrics below, Novavax, Inc. leads on 14 and Intellia Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | NTLA | NVAX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 78.60% | 65.16% |
| Operating margin | (711.66%) | (56.58%) | 0.00% |
| Net margin | (672.16%) | (59.87%) | 0.00% |
| Free cash flow margin | (585.82%) | (10.20%) | 0.00% |
| Return on equity | (55.44%) | 323.66% | (57.72%) |
| Return on assets | (45.55%) | (21.62%) | (49.22%) |
| Return on invested capital | (91.28%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack